Short answer
SelectQuote, Inc. (SLQT) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $431M (up 5.6% year over year) with net income of $40M.
Q1 2026 key financials · XBRL
- Revenue
- $431M
- +5.6% YoY · −19.8% QoQ
- Net income
- $40M
- +54.5% YoY · −42.0% QoQ
- Operating margin
- 8.3%
- EPS (diluted)
- $0.10
- +25.0% YoY · −63.0% QoQ
Source: XBRL data from the SelectQuote, Inc. (SLQT) Q1 2026 10-Q on SEC EDGAR. USD.
SelectQuote, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $430.9M, up 6% YoY from $408.2M, driven by commissions and pharmacy growth
- Net income $40.2M, 9% margin vs $26.0M and 6% YoY
- Best segment Healthcare Services: pharmacy revenue $195.3M, up 5%; 116,616 SelectRx members, up 11%
- Worst segment Life: total premiums $46.4M, down 0.4% from $46.6M
- Pharmacy headwind: $13.4M manufacturer refunds reclassified against cost of goods sold under the Inflation Reduction Act
Risk Factors
- New NYSE compliance risk triggered by March 19, 2026 notice for 30-day average share price below $1.00
- Delisting risk after six-month cure period if both $1.00 share price and 30-day average remain unmet
- Market-value risk from potential delisting reducing liquidity, trading volume, and equity-financing access
- Near-term performance risk from share-price volatility beyond management control during the cure period
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other SelectQuote, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.